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Although drug-related problems are a major source of
morbidity, the literature provides little information re-
garding utilization of ambulatory care resources for
drug-related problems. 
OBJECTIVE: The purpose of this study was to examine
the nature and extent of the use of ambulatory care services
due to adverse effects of medications in the United States. 
METHODS: This study analyzed patient records ab-
stracted from the 1996 National Ambulatory Medical
Care Survey and the National Hospital Ambulatory
Medical Care Survey. Patient visits resulting in principal
diagnoses of adverse effects of medications (ICD-9-CM
E-code 930.00–947.9) were analyzed. The resource utili-
zation and demographics associated with these visits
were examined using descriptive statistics. 
RESULTS: During 1996, 0.31% of the visits to ambulatory
settings were due to adverse effects of medications, repre-
senting an estimated 2.73 million visits per year or 1.03 vis-
its per 100 persons. The majority (87.64%) were office-
based visits. Emergency and outpatient department visits
were 7.97% and 4.39%, respectively. Visit rates for drug-
related problems were highest in whites, females, patients
over 74 years old, and patients in the West. The therapeutic
agents most often responsible for these visits were antibiot-
ics (20.36%), cardiovascular drugs (10.66%), and hor-
mones and synthetic substitutes (7.68%). The most fre-
quently cited primary reasons for the visits were skin rash
(9.89%), cough (8.56%), and adverse effect of medications
(6.52%). Other than blood pressure and blood tests, few di-
agnostic or screening services were utilized for the patients.
The medications most frequently prescribed to treat these
problems were corticosteroids, antihistamines, and drugs
for GI disorders. The majority (81.54%) of the drug-related
visits included instructions for a return visit and 1.40% of
the drug-related visits resulted in hospital admission. 
CONCLUSION: Utilization patterns due to drug-related
problems can pose a significant burden on ambulatory
care resources. Pharmaceutical care can play an impor-
tant role in reducing these problems.
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AN EMPIRICAL ANALYSIS ON AMBULATORY 
CARE UTILIZATION: APPLICATION OF A 
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Sengupta N, Nichol MB
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Very little has been done to model the utilization of am-
bulatory care empirically. 
OBJECTIVE: The purpose of this study is to estimate the
expected frequency of outpatient visits from the sociode-
mographic characteristics, health status, and comorbidities. 
METHOD: A randomized sample of 6000 southern Cali-
fornia patients with chronic diseases in a managed care en-
vironment were surveyed longitudinally during 1992–
1995. Simultaneously, healthcare utilization data were col-
lected from electronic data files. An expected frequency
count data model was developed by Poisson regression.
The frequency of outpatient visits from baseline was used
as a lagged dependent variable in the equation. Sociodemo-
graphic variables were used as covariates. Model over-
dispersion was corrected by appropriate power transforma-
tion. Model validity was also compared with the ordinary
least square model and the general linear model. 
RESULTS: More than 75% of the sample had five or
more outpatient visits during demonstration period with
a mean of 15 visits per patient. The model showed that
age, gender, and baseline visit were significant predictors
(p  0.0001) of future outpatient visit. Patient’s chronic
disease status along with three of the eight SF-36 health
status domains measured at baseline (bodily pain, general
health, role limitation due to physical problem) were also
statistically significant (p  0.005) in explaining the vari-
ations in future outpatient visits. Asian patients were less
likely to use ambulatory care facilities than other races
and female patients experienced greater utilization than
males. Income and employment status significantly af-
fected outpatient utilization. The count data model was
superior to the other models.
CONCLUSION: This study provided a useful alternative
empirical method to model count data in ambulatory care.
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NCQA accreditation is a “Good Housekeeping Seal” for
MCOs to evaluate how well a health plan manages its
clinical and administrative systems in continuously im-
proving healthcare for its members. A key standard in
NCQA accreditation is demonstrating quality improve-
ment. This case study outlines how manufacturer-funded
outcomes research was used by an MCO for the NCQA
quality improvement standard. 
OBJECTIVE: A national MCO and its behavioral health
carve-out sought to understand current prescribing prac-
tices by its primary care physicians and psychiatrists for the
patient population receiving antidepressant prescriptions. 
METHODS: Cross-sectional retrospective analyses were
conducted using the prescription, diagnosis, and eligibility
databases of the national MCO and its behavioral health
subsidiary. The population included adults who received
at least one antidepressant prescription in mid-1995. 
RESULTS: By prescriber type, 77% of patients who re-
ceived an antidepressant prescription from a psychiatrist
also had a depression diagnosis, compared to only 32%
of patients who were prescribed an antidepressant by a
primary care physician. Overall, only 34% of patients
treated with antidepressant also received a recorded de-
pression diagnosis. 
CONCLUSIONS: Based on these findings, the MCO and
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its behavioral health carve-out implemented interven-
tions directed at primary care physicians and psychia-
trists to improve the recognition and treatment of depres-
sion. A collaborative follow-up study is now under way
to compare more recent data to the original baseline find-
ings to demonstrate improvement in the quality of care
provided to antidepressant patients.
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UNDERSTANDING THE PROCESS AND ROLE OF 
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Little information exists regarding how health mainte-
nance organizations (HMOs) analyze medical technolo-
gies using technology assessment (TA).
OBJECTIVE: To describe characteristics, processes, and
roles of TA in large HMOs.
METHODS: The target survey population was large
HMOs (enrollments 100,000). One hundred and sixty-
five HMOs met this criterion. Corporate consolidation of
HMOs reduced the cohort to 96 HMOs, representing
77% of total US covered lives. A questionnaire was de-
veloped and field tested. The survey was mailed to pre-
identified HMO contacts in early 1998.
RESULTS: Survey response rate was 43%. Of respondents,
85% (35/41) routinely conduct TA. More than 50% of the
time, TA in HMOs includes representatives from medical,
pharmacy, quality improvement, legal, and benefits func-
tions. TA is initiated by HMO medical affairs departments
(70% of the time). HMOs conduct TA on equipment,
procedures, devices, and several types of drugs. All respon-
dents conduct TA either at time of product introduction,
adoption into practice, or upon FDA approval. HMOs con-
duct TA again for one of three reasons: competitive alterna-
tives, new indication, or replacement. Legislative, societal,
and accreditation demands can influence HMOs to conduct
TA. HMOs consider randomized controlled trials, pub-
lished in peer reviewed journals as the most desirable data
source. Other data are used, but were rated less favorably.
Lack of timely data can limit TA. Over 90% of respondents
seek outside assistance for TA. HMOs typically conduct TA
to determine benefits coverage policy.
CONCLUSION: Most HMOs surveyed conduct TA.
Medical staff influence TA in HMOs. HMOs perceive ran-
domized controlled trials as more desirable than other
data. Outcomes data are often not available at time of TA.
HMOs use TA consultants as one source of information.
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PRESENTATION OF DESCRIPTIVE STATISTICS
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OBJECTIVE: Cost-effective data collection is a critical
component of pharmacoeconomic and outcomes studies,
and is often a key limiter of study design and scope. The
objectives of this presentation are to: 1) present a new
method of clinical data collection in the community-based
physician setting, and 2) present statistics on data collected
in 1998. 
METHODS: This presentation focuses on collecting clin-
ical information in the community-based physician set-
ting. This information has broad utility, including sup-
port of the conduct of pharmacoeconomic and outcomes
studies. The data collection process is built around com-
munity-based physicians’ preferred means of document-
ing patient encounters—dictation and transcription. The
data collection process begins with templated physician
dictation to support discrete data element capture. New
transcription technologies that provide for discrete data
element capture, in addition to free text typing, are used
to document the encounter and capture the data ele-
ments. Back-end data scrubbing, natural language encod-
ing, and data mapping are then used to transform physi-
cian natural language into useable data. Techniques for
validating data through source document sampling will
also be presented. 
RESULTS: Data collected from cardiologists through
September 1998 will be presented. Preliminary statistics
include the following: 5865 coronary artery disease pa-
tients were seen; 54.1% of these patients were on a sta-
tin. Of these patients 42.1% were on atorvastatin, 36.7%
were on simvastatin, 11.2% were on pravastatin, and
10.0% were on other statins. Switching patterns between
statins will be presented. Common switching reasons in-
clude formulary changes, ineffectiveness and side effects. 
CONCLUSIONS: Existing clinical documentation pro-
cesses can be leveraged to collect more detailed and mean-
ingful information for pharmacoeconomics and outcomes
studies than traditional, transaction-based information
sources.
PPO12
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OBJECTIVES: Using prescription claims data, the pri-
mary objective of this study was to evaluate whether uti-
lization differed among various plan characteristics after
controlling for covariates. The secondary objective was
to examine the relationships among plan characteristics
and cost of pharmaceuticals within various therapeutic
categories.
METHODS: Data were obtained from 1996 prescription
claims information for the commercial population ad-
ministered by a Rhode Island–based PBM. There were
29,211 subscribers representing 64,815 enrollees eligible
